Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research11

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research11

FiltersClear all

Status

Recruiting2
Enrolling by invitation1
Active, not recruiting3
Completed5

Study type

Interventional11
Observational1

Phase

Not applicable4
Phase 23
Phase 33
Phase 41

Investigator

Evelyn M. Horn3
Georgiana Alina Dobri2
Dmitriy N. Feldman1
Daniel W Skupski1
Erica Phillips1

Department

Medicine8
Neurological Surgery2
Emergency Medicine1
Obstetrics and Gynecology1

Condition

Hypertension11
Leukemia, Myeloid, Acute50
Prostatic Neoplasms49
Breast Neoplasms41
Heart Failure31

Intervention type

Drug7
Other4
Behavioral3
Device1

Sponsor type

Industry6
WCM (investigator-initiated)3
Other academic2

Start date

Has results posted5

Interventional×Hypertension×Clear all

Showing 1–11 of 11 studiesSort:

Active, not recruitingInterventional · Phase 2NCT03604198 ↗
An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome

FiltersClear all

Status

Recruiting2
Enrolling by invitation1
Active, not recruiting3
Completed5

Study type

Interventional11
Observational1

Phase

Not applicable4
Phase 23
Phase 33
Phase 41

Investigator

Evelyn M. Horn3
Georgiana Alina Dobri2
Dmitriy N. Feldman1
Daniel W Skupski1
Erica Phillips1

Department

Medicine8
Neurological Surgery2
Emergency Medicine1
Obstetrics and Gynecology1

Condition

Hypertension11
Leukemia, Myeloid, Acute50
Prostatic Neoplasms49
Breast Neoplasms41
Heart Failure31

Intervention type

Drug7
Other4
Behavioral3
Device1

Sponsor type

Industry6
WCM (investigator-initiated)3
Other academic2

Start date

Has results posted5

Interventional×Hypertension×Clear all

Showing 1–11 of 11 studiesSort:

Active, not recruitingInterventional · Phase 2NCT03604198 ↗
An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome

Show all 9

Show fewer

Jennifer A Downs1
Junaid Razzak1
Margaret McNairy1
Phyllis August1

Show all 50

Show fewer

Neoplasms31
Carcinoma, Non-Small-Cell Lung27
Multiple Myeloma27
Colitis, Ulcerative26
Crohn Disease26
Myelodysplastic Syndromes26
Recurrence25
Atrial Fibrillation23
Neoplasm Metastasis23
Obesity23
Parkinson Disease21
COVID-1920
Colorectal Neoplasms18
Depression18
Cardiovascular Diseases17
Hematologic Neoplasms17
HIV Infections16
Non-alcoholic Fatty Liver Disease15
Overweight15
Melanoma13
Idiopathic Pulmonary Fibrosis12
Inflammatory Bowel Diseases12
Leukemia, Lymphocytic, Chronic, B-Cell12
Lung Neoplasms12
Lymphoma, Non-Hodgkin12
Primary Myelofibrosis12
Myeloproliferative Disorders11
Alzheimer Disease10
Coronary Artery Disease10
Hypertension, Pulmonary10
Leukemia, Myelomonocytic, Chronic10
Stroke10
Urinary Bladder Neoplasms10
Cognitive Dysfunction9
Leukemia9
Lung Diseases, Interstitial9
Pulmonary Arterial Hypertension9
Burkitt Lymphoma8
Carcinoma, Renal Cell8
Chronic Pain8
Fibrosis8
Lymphoma, Follicular8
Lymphoma, Large B-Cell, Diffuse8
Adenocarcinoma Of Esophagus7
Anemia7

Georgiana Alina DobriPI

Intervention: Drug: relacorilant
Dates: May 2018 – Dec 2026 (est.)
Sponsor: Corcept Therapeutics Incorporated

Cushing Syndrome

Enrolling by invitationInterventional · Phase 3NCT03683186 ↗

A Phase 3 Open-label Extension (OLE) Study to Evaluate the Long-term Safety and Efficacy of Ralinepag in Subjects With World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH)

Evelyn M. HornPI

Intervention: Drug: Ralinepag
Dates: Sep 2019 – Dec 2026 (est.)
Sponsor: United Therapeutics

PAHPulmonary HypertensionPulmonary Arterial Hypertension+8 more

Active, not recruitingInterventional · Not applicableNCT05198674 ↗

The SPYRAL AFFIRM Global Clinical Study of Renal Denervation With the Symplicity Spyral Renal Denervation System in Subjects With Uncontrolled Hypertension (SPYRAL AFFIRM)

Dmitriy N. FeldmanPI

Intervention: Device: Renal Denervation (Symplicity Spyral™)
Dates: Oct 2021 – Mar 2026
Sponsor: Medtronic, Inc.

HypertensionVascular DiseasesCardiovascular Diseases+2 more

RecruitingInterventional · Not applicableNCT05416372 ↗

Engaging Religious Leaders to Reduce Blood Pressures in Tanzanian Communities

Jennifer A DownsPI

Intervention: Behavioral: Religious Engagement in Health Intervention
Dates: Jun 2022 – Jul 2025· Results posted
Sponsor: Weill Medical College of Cornell University

Hypertension

Active, not recruitingInterventional · Not applicableNCT05885997 ↗

Implementing a Home Blood Pressure Monitoring Program to Improve Hypertension Control in a Primary Care Network: the MonitorBP Cluster Randomized Trial

Erica PhillipsPI

Intervention: Behavioral: Supported HBPM program plus multifaceted implementation strategy · Other: Usual care
Dates: Nov 2023 – Oct 2026
Sponsor: Columbia University

Hypertension

RecruitingInterventional · Not applicableNCT07461415 ↗

CONNECT-HTN Trial - Coaching and Navigation by CHWs Through Telehealth for High-risk Hypertension

Junaid RazzakPI

Intervention: Behavioral: CONNECT-HTN · Other: Standard ED management
Dates: Mar 2026 – Aug 2029 (est.)
Sponsor: Weill Medical College of Cornell University

Hypertension

CompletedInterventional · Phase 4NCT02299414 ↗

A Pragmatic Multicenter Randomized Clinical Trial (RCT) of Antihypertensive Therapy for Mild Chronic Hypertension During Pregnancy: Chronic Hypertension and Pregnancy (CHAP) Project

Phyllis AugustPIDaniel W SkupskiPI

Intervention: Drug: Anti-hypertensive therapy · Other: No anti-hypertensive therapy (unless BP is severe)
Dates: Jun 2015 – Apr 2022· Results posted
Sponsor: University of Alabama

Hypertension

CompletedInterventional · Phase 3NCT03626688 ↗

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH

Evelyn M. HornPI

Intervention: Drug: Ralinepag · Drug: Placebo
Dates: Jan 2019 – Dec 2025
Sponsor: United Therapeutics

PAHPulmonary HypertensionPulmonary Arterial Hypertension+8 more

CompletedInterventional · Phase 3NCT04308590 ↗

Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients With Cortisol-Secreting Adrenal Adenomas or Hyperplasia (GRADIENT): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Relacorilant

Georgiana Alina DobriPI

Intervention: Drug: Relacorilant · Other: Placebo
Dates: Jul 2020 – Sep 2024· Results posted
Sponsor: Corcept Therapeutics Incorporated

Hypercortisolism

CompletedInterventional · Phase 2NCT04692467 ↗

Treatment of Early Hypertension Among Persons Living With HIV in Haiti

Margaret McNairyPI

Intervention: Drug: Amlodipine 5mg
Dates: Feb 2021 – Jun 2023· Results posted
Sponsor: Weill Medical College of Cornell University

HIV/AIDSPre Hypertension

CompletedInterventional · Phase 2NCT04945460 ↗

A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept Versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) Due to Heart Failure With Preserved Ejection Fraction (HFpEF)

Evelyn M. HornPI

Intervention: Drug: Sotatercept 0.3 mg/kg · Drug: Placebo · Drug: Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
Dates: Dec 2021 – Sep 2025· Results posted
Sponsor: Acceleron Pharma, Inc.

Hypertension, Pulmonary